For a company that rarely misses earning expectations and is typically viewed as a credible commentator on near-term economic conditions, Danaher's (NYSE:DHR) third quarter results can't leave investors feeling too great. Although the company's long-term strategy of growth-through-acquisition and fierce cost efficiency is very likely to continue, the near-term outlook has definitely worsened. Given that this stock has often sported a premium multiple, performance could continue to lag until investors feel more optimistic about the macro outlook.

Credit Card Comparison: Find the credit card that is just right for you

Another Disappointing Quarter
Although Danaher management lowered guidance back at the second quarter, apparently they did not go far enough, as the company posted a modest miss. Perhaps more concerning for long-term shareholders are the signs that the focus on M&A in the life sciences/healthcare space hasn't yet really paid dividends.

Revenue fell 2% as reported for the third quarter, with organic revenue up just 1%. Although only a relatively small number of major industrials have reported so far, Danaher's results fit broadly in with Dover (NYSE:DOV) and Honeywell (NYSE:HON), though behind longer-tail names like General Electric (NYSE:GE) and Textron (NYSE:TXT).

Gross margin improved more than three points for the quarter. Operating performance was more mixed, due in large part to various charges and items. Looking at the core segment earnings, profits were pretty much flat on a year-on-year basis.

SEE: Everything Investors Need To Know About Earnings

No Real Areas of Strength
Unfortunately, Danaher didn't really have any particularly bright spots for the quarter. The economically-sensitive test and measurement business was down about 5% as reported, with Fluke down in the double-digits. That's reason for pause, as Fluke has often been a pretty solid barometer of real-time economic conditions. It's also not great news for Agilent (NYSE:A), though their businesses do not line up exactly.

Environmental segment revenue rose 3%, while life sciences and industrial tech fell 3% each and dental dropped 1%. Contrary to some of the early reports I've read, I'm not that bothered by the life science results. I don't see any particular reason to think that Agilent or Thermo Fisher (NYSE:TMO) are going to have great quarters in their life science businesses. On a more positive note, Beckman continues to come along, and I think this will be a case of "slow and steady wins the race."

SEE: How To Decode A Company's Earnings Reports

Judging a Long-Term Story by Short-Term Results
I've long had some issues with Danaher's valuation, but I have never questioned the company's model or its prospects for better-than-peer long-term growth. Said differently, I'd be careful about selling a long-held position just because of rocky going in the short-term.

The short term does seem to be getting rockier. Management lowered guidance again and seemed pretty cautious (if not bearish). At the same time, it seems like some investors and analysts are raising more questions about the company's recent M&A dealings and questioning whether management has lost its mojo. Once again, I think this is a case of differing time horizons; the life science and healthcare markets are definitely soft right now (and softer than most companies thought they'd be), but I have a hard time seeing how or why the long-term growth won't materialize as emerging markets spend more money on healthcare and more developed economies deal with their aging populations.

SEE: Mergers And Acquisitions: Introduction

The Bottom Line
Danaher has a history of delivering better growth than other industrial comps like Dover and Illinois Tool Works (NYSE:ITW), and the valuation reflects that higher ongoing growth expectation. That said, I have my doubts as to whether that outsized growth can continue - more as a consequence of Danaher's size than any emergent deficiencies in the business.

Even with an estimate of high single-digit free cash flow growth, these shares don't look especially cheap. For these shares to be undervalued by the market today, management needs to either lift (and sustain) free cash flow margins in the high teens or revenue growth in the high single digits. Either implies a decade-long average of over 10% compound free cash flow growth, and that's a pretty aggressive assumption, even for a well-run company like Danaher.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center